Speakers: Sergei Ananyan & Sam Montgomery

AI is transforming early-stage drug discovery by accelerating key tasks such as target identification, molecular design, virtual screening, ADMET prediction, and drug repurposing. In this webinar, we’ll focus on one of the most critical steps: using AI agents to speed up target identification.

By combining scientific literature with experimental and omics data, AI can help prioritize disease-relevant genes, proteins, and pathways – enabling faster generation and evaluation of therapeutic hypotheses. This supports both target-based discovery and indication expansion for novel or existing molecules.

Building reliable, pathway-centric knowledge systems isn’t easy. Data volume, quality, bias, and integration remain major challenges.

Topics covered:

• Prioritizing disease-relevant genes, proteins, and pathways with AI
• Creating AI agents without coding
• Typical challenges and how to overcome them
• Live demo of a practical solution and results